Transcultural Validation of the French Version of the " Patients' Endorsement of a Biopsychosocial Model of Chronic Pain " Scale
- Conditions
- Pain, Chronic
- Registration Number
- NCT06698406
- Lead Sponsor
- Benno Rehberg-Klug
- Brief Summary
We will validate the French version of the "Patients' Endorsement of a Biopsychosocial model of chronic pain (PEB) scale" by comparing it to the "pain self-efficacy" questionnaire
- Detailed Description
The primary objective is to validate the French version of the PEB scale, called "Echelle d'Adhésion du modèle Bio-psycho-social par des patients avec Douleur Chronique ABDC".
The hypothesis is that the ABDC scale is a valid measurement tool to measure and operationalize beliefs about the biopsychosocial nature of pain in adults with chronic pain.
Consenting patients will receive paper copies of the study questionnaire including the questionnaires named in the secondary outcomes section, except those which are already included in the standard evaluation questionnaire of the pain consultation (BPI, GAD-7, PHQ-9). Patients will return the questionnaire either at a the same or a follow-up consultation, or send in the questionnaire by post in a prepaid envelope.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 80
-
- Patients with chronic pain (defined by ICD-11 as pain persisting or recurring longer than 3 months) having a chronic pain consultation at the HUG
- French-speaking and able to understand the study information
- ≥18 years of age
-
- Inability to understand the consent form and the questionnaire, e.g. due to lan-guage problems, psychological disorders, dementia, etc. of the participant
- Enrolment of the investigator, his/her family members, employees and other de-pendent persons
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incremental validity of the new ABDC scale 1 day Incremental validity is the degree to which a new scale increases the ability to predict an outcome beyond existing parameters and scales. In our case pain self-efficacy, measured by the "pain self-efficacy questionnaire" \[8\], which exists in a validated French version \[9\], is the outcome to be predicted.
Hierarchical regression analysis will have four models including in hierarchical order 8 explanatory variables: demographical variables (gender, age, level of education), depressive symptoms and anxiety, pain catastrophizing, pain acceptance, and finally the ABDC scale
- Secondary Outcome Measures
Name Time Method Reliability of the ABDC scale 1 day Reliability will be evaluated as internal consistency, measured by Cronbach's alpha and corrected item-total-correlations.
Convergent validity 1 day Convergent validity will be evaluated by the correlation between the ABDC scale sum score and the "Survey of Pain Attitudes SOPA" scale \[10\], a self-administered questionnaire with 57 statements evaluating 7 categories of beliefs and attitudes about pain.
Discriminant validity 1 day correlations with the following scales which measure constructs which are important determinants of chronic pain severity, but independent of the endorsement of the biopsychosocial model by a patient: Brief Pain Inventory (BPI) The Brief Pain Inventory (BPI) \[11\] is a tool used to assess pain in patients. It was developed to measure both the intensity of pain and its impact on the patient's daily life. We will evaluate correlations with both the BPI-pain severity and the BPI-pain interference subscores.
Generalized anxiety disorder questionnaire GAD-7 The GAD-7 \[12\] is a questionnaire used to assess generalized anxiety disorder. It consists of seven questions that evaluate different symptoms associated with anxiety, such as nervousness, restlessness, and difficulty controlling worry.
Depressive symptoms: patient heath questionnaire PHQ-9 The PHQ-9 \[13\] is a screening tool for depression. It includes nine quest
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Hôpitaux Universitaires de Genève
🇨🇭Genève, Switzerland